 Megan Adams
Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 28 | 2025 | 831 | 6.410 |
Why?
| | Gastroenterology | 10 | 2024 | 174 | 3.930 |
Why?
| | Anesthesia | 6 | 2023 | 134 | 3.540 |
Why?
| | Delivery of Health Care, Integrated | 4 | 2023 | 248 | 2.410 |
Why?
| | Ambulatory Care | 4 | 2024 | 504 | 2.180 |
Why?
| | Endoscopy, Gastrointestinal | 7 | 2023 | 219 | 2.070 |
Why?
| | Colonoscopy | 9 | 2023 | 236 | 2.020 |
Why?
| | United States Department of Veterans Affairs | 9 | 2024 | 635 | 1.890 |
Why?
| | Colorectal Neoplasms | 5 | 2023 | 752 | 1.880 |
Why?
| | Liability, Legal | 5 | 2021 | 40 | 1.850 |
Why?
| | Living Donors | 12 | 2025 | 287 | 1.760 |
Why?
| | Malpractice | 4 | 2021 | 38 | 1.600 |
Why?
| | Veterans Health | 4 | 2023 | 178 | 1.400 |
Why?
| | Gastroenterologists | 2 | 2017 | 18 | 1.120 |
Why?
| | Telemedicine | 3 | 2024 | 788 | 1.070 |
Why?
| | Outpatients | 3 | 2020 | 370 | 1.050 |
Why?
| | Hepatoblastoma | 2 | 2023 | 41 | 1.050 |
Why?
| | Biliary Atresia | 3 | 2025 | 161 | 1.030 |
Why?
| | Practice Guidelines as Topic | 4 | 2018 | 1501 | 0.990 |
Why?
| | Liver Cirrhosis | 2 | 2024 | 280 | 0.970 |
Why?
| | Retrospective Studies | 24 | 2025 | 14518 | 0.940 |
Why?
| | Health Services Accessibility | 4 | 2024 | 902 | 0.920 |
Why?
| | Liver Neoplasms | 3 | 2024 | 640 | 0.910 |
Why?
| | End Stage Liver Disease | 3 | 2023 | 78 | 0.910 |
Why?
| | United States | 22 | 2024 | 13903 | 0.910 |
Why?
| | Humans | 75 | 2025 | 129652 | 0.910 |
Why?
| | Donor Selection | 2 | 2021 | 75 | 0.870 |
Why?
| | Delivery of Health Care | 3 | 2021 | 894 | 0.840 |
Why?
| | Veterans | 4 | 2024 | 1398 | 0.790 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2024 | 320 | 0.780 |
Why?
| | Tissue and Organ Procurement | 3 | 2022 | 288 | 0.760 |
Why?
| | International Classification of Diseases | 1 | 2022 | 122 | 0.750 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2021 | 24 | 0.740 |
Why?
| | Airway Extubation | 1 | 2022 | 54 | 0.740 |
Why?
| | Tissue Donors | 2 | 2021 | 391 | 0.740 |
Why?
| | Endoscopy, Digestive System | 2 | 2020 | 122 | 0.730 |
Why?
| | Early Detection of Cancer | 4 | 2023 | 370 | 0.730 |
Why?
| | Gastrointestinal Diseases | 2 | 2024 | 198 | 0.720 |
Why?
| | Graft Survival | 8 | 2023 | 512 | 0.690 |
Why?
| | Sexism | 1 | 2021 | 55 | 0.680 |
Why?
| | Clinical Decision-Making | 2 | 2021 | 303 | 0.650 |
Why?
| | Personal Autonomy | 1 | 2020 | 48 | 0.650 |
Why?
| | Waiting Lists | 4 | 2022 | 237 | 0.640 |
Why?
| | Strikes, Employee | 1 | 2019 | 1 | 0.630 |
Why?
| | Gastrointestinal Tract | 1 | 2021 | 185 | 0.610 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2021 | 282 | 0.590 |
Why?
| | Collective Bargaining | 1 | 2017 | 2 | 0.580 |
Why?
| | Patient Preference | 1 | 2020 | 185 | 0.570 |
Why?
| | Capitation Fee | 1 | 2017 | 14 | 0.570 |
Why?
| | Anesthesiologists | 1 | 2017 | 11 | 0.570 |
Why?
| | Community Health Services | 1 | 2019 | 227 | 0.560 |
Why?
| | Reimbursement, Incentive | 1 | 2017 | 36 | 0.550 |
Why?
| | Drug Overdose | 1 | 2021 | 322 | 0.550 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2017 | 94 | 0.540 |
Why?
| | Risk Management | 2 | 2016 | 85 | 0.540 |
Why?
| | Tape Recording | 1 | 2016 | 13 | 0.540 |
Why?
| | Kidney Transplantation | 2 | 2020 | 672 | 0.530 |
Why?
| | Nurses | 1 | 2019 | 164 | 0.520 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 2 | 2015 | 206 | 0.500 |
Why?
| | Employment | 1 | 2017 | 167 | 0.500 |
Why?
| | Postoperative Complications | 4 | 2024 | 2483 | 0.500 |
Why?
| | Blood Coagulation Disorders | 3 | 2023 | 167 | 0.500 |
Why?
| | Quality of Health Care | 2 | 2017 | 608 | 0.490 |
Why?
| | Trust | 1 | 2016 | 116 | 0.480 |
Why?
| | Withholding Treatment | 1 | 2015 | 71 | 0.480 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2015 | 17 | 0.480 |
Why?
| | Choledocholithiasis | 1 | 2015 | 14 | 0.480 |
Why?
| | Hospitalization | 2 | 2024 | 2070 | 0.470 |
Why?
| | Unnecessary Procedures | 1 | 2015 | 48 | 0.460 |
Why?
| | Acute Kidney Injury | 1 | 2022 | 790 | 0.460 |
Why?
| | Disease Management | 1 | 2018 | 589 | 0.460 |
Why?
| | Medical Errors | 2 | 2021 | 104 | 0.450 |
Why?
| | Colonic Polyps | 1 | 2015 | 87 | 0.450 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 484 | 0.440 |
Why?
| | Endosonography | 1 | 2015 | 143 | 0.430 |
Why?
| | Tissue Plasminogen Activator | 4 | 2023 | 222 | 0.430 |
Why?
| | Child | 14 | 2023 | 20883 | 0.430 |
Why?
| | Diagnostic Errors | 1 | 2014 | 162 | 0.420 |
Why?
| | Disclosure | 1 | 2014 | 110 | 0.410 |
Why?
| | Physician-Patient Relations | 2 | 2021 | 539 | 0.410 |
Why?
| | Patient Participation | 1 | 2016 | 414 | 0.400 |
Why?
| | Aspirin | 1 | 2015 | 380 | 0.390 |
Why?
| | Case-Control Studies | 3 | 2024 | 3381 | 0.390 |
Why?
| | Attitude of Health Personnel | 2 | 2019 | 1098 | 0.380 |
Why?
| | Esophageal Neoplasms | 2 | 2017 | 295 | 0.380 |
Why?
| | Conscious Sedation | 2 | 2023 | 85 | 0.370 |
Why?
| | Guideline Adherence | 1 | 2015 | 526 | 0.370 |
Why?
| | Middle Aged | 17 | 2024 | 31155 | 0.360 |
Why?
| | Occult Blood | 2 | 2022 | 30 | 0.360 |
Why?
| | Aged | 10 | 2024 | 22104 | 0.360 |
Why?
| | Decision Support Techniques | 1 | 2015 | 396 | 0.360 |
Why?
| | Male | 23 | 2025 | 63682 | 0.350 |
Why?
| | Hypnotics and Sedatives | 2 | 2023 | 175 | 0.350 |
Why?
| | Fellowships and Scholarships | 1 | 2013 | 273 | 0.340 |
Why?
| | Resuscitation | 2 | 2024 | 237 | 0.340 |
Why?
| | Mass Screening | 3 | 2023 | 1149 | 0.330 |
Why?
| | Female | 22 | 2025 | 68777 | 0.320 |
Why?
| | Physicians | 1 | 2017 | 865 | 0.310 |
Why?
| | Databases, Factual | 3 | 2021 | 1269 | 0.310 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1266 | 0.300 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2017 | 339 | 0.300 |
Why?
| | Endoscopy | 2 | 2022 | 285 | 0.300 |
Why?
| | Infant | 7 | 2025 | 9024 | 0.290 |
Why?
| | Thrombelastography | 4 | 2022 | 150 | 0.290 |
Why?
| | Treatment Outcome | 10 | 2025 | 10230 | 0.290 |
Why?
| | Adenocarcinoma | 1 | 2014 | 898 | 0.280 |
Why?
| | Fibrinolysis | 3 | 2023 | 137 | 0.270 |
Why?
| | Graft Rejection | 2 | 2020 | 598 | 0.260 |
Why?
| | Blood Coagulation | 3 | 2023 | 238 | 0.240 |
Why?
| | Adult | 11 | 2024 | 35577 | 0.240 |
Why?
| | Longitudinal Studies | 2 | 2022 | 2717 | 0.230 |
Why?
| | Risk Factors | 6 | 2025 | 9765 | 0.230 |
Why?
| | Registries | 3 | 2021 | 1896 | 0.220 |
Why?
| | Cardiovascular Diseases | 1 | 2015 | 2004 | 0.210 |
Why?
| | Endoscopes, Gastrointestinal | 1 | 2023 | 14 | 0.210 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 15 | 0.200 |
Why?
| | Liver Failure | 1 | 2023 | 91 | 0.200 |
Why?
| | Primary Graft Dysfunction | 1 | 2023 | 29 | 0.200 |
Why?
| | Communication | 3 | 2023 | 846 | 0.200 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 64 | 0.200 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2024 | 272 | 0.200 |
Why?
| | Informed Consent | 2 | 2021 | 170 | 0.190 |
Why?
| | Propensity Score | 1 | 2023 | 265 | 0.190 |
Why?
| | Renal Replacement Therapy | 1 | 2022 | 87 | 0.190 |
Why?
| | Portoenterostomy, Hepatic | 1 | 2022 | 45 | 0.190 |
Why?
| | Survival Rate | 2 | 2023 | 1877 | 0.190 |
Why?
| | Sarcoma | 1 | 2023 | 176 | 0.180 |
Why?
| | Risk Assessment | 3 | 2022 | 3240 | 0.180 |
Why?
| | Transplant Recipients | 2 | 2020 | 162 | 0.180 |
Why?
| | Adolescent | 5 | 2023 | 20394 | 0.180 |
Why?
| | Uncertainty | 1 | 2021 | 116 | 0.180 |
Why?
| | Young Adult | 4 | 2023 | 12427 | 0.180 |
Why?
| | Logistic Models | 2 | 2017 | 1988 | 0.180 |
Why?
| | Policy | 1 | 2022 | 144 | 0.170 |
Why?
| | Reperfusion | 1 | 2020 | 38 | 0.170 |
Why?
| | Feasibility Studies | 1 | 2024 | 868 | 0.170 |
Why?
| | Health Facilities | 1 | 2021 | 80 | 0.170 |
Why?
| | Child, Preschool | 4 | 2022 | 10517 | 0.170 |
Why?
| | Infant, Newborn | 5 | 2025 | 5762 | 0.170 |
Why?
| | Preoperative Care | 1 | 2022 | 340 | 0.170 |
Why?
| | Short Bowel Syndrome | 1 | 2020 | 26 | 0.170 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 45 | 0.170 |
Why?
| | Blood Component Transfusion | 1 | 2020 | 82 | 0.170 |
Why?
| | Liver | 3 | 2022 | 1839 | 0.160 |
Why?
| | Compensation and Redress | 1 | 2019 | 7 | 0.160 |
Why?
| | Hospitals, Teaching | 1 | 2020 | 113 | 0.160 |
Why?
| | Cause of Death | 1 | 2021 | 393 | 0.160 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 283 | 0.160 |
Why?
| | Ethics, Medical | 1 | 2020 | 78 | 0.160 |
Why?
| | Organizational Objectives | 1 | 2019 | 73 | 0.160 |
Why?
| | Digestive System Surgical Procedures | 1 | 2020 | 96 | 0.160 |
Why?
| | Referral and Consultation | 1 | 2024 | 733 | 0.160 |
Why?
| | Perioperative Care | 1 | 2020 | 152 | 0.160 |
Why?
| | Immunocompromised Host | 1 | 2020 | 198 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1368 | 0.150 |
Why?
| | Horses | 1 | 2019 | 107 | 0.150 |
Why?
| | Educational Status | 1 | 2021 | 470 | 0.150 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2018 | 17 | 0.150 |
Why?
| | Health Care Reform | 1 | 2019 | 101 | 0.150 |
Why?
| | Labor Unions | 1 | 2017 | 4 | 0.150 |
Why?
| | Investments | 1 | 2017 | 6 | 0.140 |
Why?
| | Pandemics | 2 | 2023 | 1488 | 0.140 |
Why?
| | Respiration, Artificial | 1 | 2022 | 613 | 0.140 |
Why?
| | Pneumoperitoneum | 1 | 2017 | 12 | 0.140 |
Why?
| | Klebsiella Infections | 1 | 2017 | 25 | 0.140 |
Why?
| | Michigan | 2 | 2016 | 104 | 0.140 |
Why?
| | Cholecystitis | 1 | 2017 | 23 | 0.140 |
Why?
| | Organ Transplantation | 1 | 2020 | 228 | 0.140 |
Why?
| | Retirement | 1 | 2017 | 26 | 0.140 |
Why?
| | Cholecystectomy | 1 | 2017 | 59 | 0.140 |
Why?
| | Medical Overuse | 1 | 2017 | 30 | 0.140 |
Why?
| | Mesalamine | 1 | 2017 | 10 | 0.140 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2017 | 17 | 0.140 |
Why?
| | Scleritis | 1 | 2017 | 19 | 0.130 |
Why?
| | Length of Stay | 1 | 2022 | 1127 | 0.130 |
Why?
| | Critical Illness | 1 | 2022 | 758 | 0.130 |
Why?
| | Pain | 1 | 2022 | 789 | 0.130 |
Why?
| | Alcoholism | 1 | 2023 | 766 | 0.130 |
Why?
| | Cost of Illness | 1 | 2018 | 278 | 0.130 |
Why?
| | Program Evaluation | 2 | 2017 | 875 | 0.130 |
Why?
| | Insurance, Health | 1 | 2018 | 267 | 0.120 |
Why?
| | Gastroesophageal Reflux | 2 | 2017 | 232 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 853 | 0.120 |
Why?
| | Colitis, Ulcerative | 1 | 2017 | 119 | 0.120 |
Why?
| | Healthcare Disparities | 1 | 2021 | 578 | 0.120 |
Why?
| | Cohort Studies | 2 | 2023 | 5420 | 0.120 |
Why?
| | Kidney Failure, Chronic | 1 | 2020 | 547 | 0.120 |
Why?
| | Parents | 2 | 2020 | 1309 | 0.120 |
Why?
| | Reproducibility of Results | 1 | 2022 | 3083 | 0.120 |
Why?
| | Odds Ratio | 1 | 2017 | 1023 | 0.110 |
Why?
| | Health Services Research | 1 | 2017 | 391 | 0.110 |
Why?
| | Chemoprevention | 1 | 2015 | 91 | 0.110 |
Why?
| | Age Factors | 1 | 2021 | 3144 | 0.110 |
Why?
| | Time Factors | 2 | 2021 | 6556 | 0.110 |
Why?
| | Pancreatitis | 1 | 2015 | 129 | 0.110 |
Why?
| | Internal Medicine | 1 | 2016 | 247 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1502 | 0.110 |
Why?
| | Patient Safety | 1 | 2016 | 287 | 0.100 |
Why?
| | Surveys and Questionnaires | 2 | 2023 | 5406 | 0.100 |
Why?
| | Quality Improvement | 2 | 2017 | 1103 | 0.100 |
Why?
| | Kidney | 1 | 2019 | 1385 | 0.100 |
Why?
| | Medicare | 1 | 2017 | 720 | 0.100 |
Why?
| | Medication Adherence | 1 | 2017 | 558 | 0.100 |
Why?
| | Motivation | 1 | 2016 | 546 | 0.100 |
Why?
| | Societies, Medical | 1 | 2015 | 751 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2012 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1838 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2017 | 975 | 0.080 |
Why?
| | Algorithms | 1 | 2015 | 1622 | 0.070 |
Why?
| | Internship and Residency | 1 | 2016 | 1053 | 0.070 |
Why?
| | Clinical Competence | 1 | 2013 | 1017 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 1952 | 0.060 |
Why?
| | Prospective Studies | 3 | 2020 | 7133 | 0.060 |
Why?
| | Biomarkers | 1 | 2015 | 3973 | 0.050 |
Why?
| | Prevalence | 2 | 2021 | 2564 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 11 | 0.050 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2022 | 27 | 0.050 |
Why?
| | Bile Ducts | 1 | 2022 | 67 | 0.050 |
Why?
| | Allografts | 1 | 2023 | 136 | 0.050 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2022 | 84 | 0.050 |
Why?
| | Adenoviridae | 1 | 2023 | 192 | 0.050 |
Why?
| | Death | 1 | 2023 | 121 | 0.050 |
Why?
| | Creatinine | 1 | 2023 | 491 | 0.050 |
Why?
| | Animals | 2 | 2023 | 35361 | 0.040 |
Why?
| | Acetaminophen | 1 | 2023 | 246 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 53 | 0.040 |
Why?
| | Computer Systems | 1 | 2020 | 44 | 0.040 |
Why?
| | Viscosity | 1 | 2020 | 90 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2020 | 112 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2020 | 152 | 0.040 |
Why?
| | Obesity | 2 | 2024 | 2883 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2023 | 1038 | 0.040 |
Why?
| | Health Expenditures | 1 | 2021 | 179 | 0.040 |
Why?
| | Markov Chains | 1 | 2020 | 117 | 0.040 |
Why?
| | Remission Induction | 1 | 2020 | 272 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 329 | 0.040 |
Why?
| | Documentation | 1 | 2021 | 184 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2020 | 401 | 0.040 |
Why?
| | Health Care Costs | 1 | 2021 | 367 | 0.040 |
Why?
| | Critical Care | 1 | 2023 | 553 | 0.040 |
Why?
| | Klebsiella pneumoniae | 1 | 2017 | 44 | 0.040 |
Why?
| | Duodenitis | 1 | 2017 | 7 | 0.040 |
Why?
| | Esophageal Fistula | 1 | 2017 | 18 | 0.030 |
Why?
| | Sigmoidoscopy | 1 | 2017 | 11 | 0.030 |
Why?
| | Esophageal Stenosis | 1 | 2017 | 51 | 0.030 |
Why?
| | Esophagitis | 1 | 2017 | 68 | 0.030 |
Why?
| | Enema | 1 | 2017 | 43 | 0.030 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2017 | 121 | 0.030 |
Why?
| | Colectomy | 1 | 2017 | 94 | 0.030 |
Why?
| | Sepsis | 1 | 2022 | 574 | 0.030 |
Why?
| | Gastritis | 1 | 2017 | 96 | 0.030 |
Why?
| | Education | 1 | 2016 | 101 | 0.030 |
Why?
| | Rectum | 1 | 2017 | 170 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1720 | 0.030 |
Why?
| | Communication Barriers | 1 | 2016 | 98 | 0.030 |
Why?
| | Barrett Esophagus | 1 | 2017 | 148 | 0.030 |
Why?
| | Diagnostic Tests, Routine | 1 | 2016 | 102 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2015 | 170 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2644 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2742 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4897 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5066 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2635 | 0.020 |
Why?
| | Mice | 1 | 2023 | 16937 | 0.020 |
Why?
|
|
Adams's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|